• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Morning Movers: MYL, DRI, GOOGL and the Pound

Brexit concerns pummel the pound while Alphabet gets set to unveil several new devices.
By ANDERS KEITZ Oct 04, 2016 | 08:17 AM EDT
Stocks quotes in this article: MYL, DRI, GOOGL, AMZN

Concerns about Brexit continue to linger as the pound fell to a 31-year low against the U.S. dollar on Tuesday, even trading below levels reached following the vote to leave the European Union in June. The currency dropped to $1.274 -- which is almost 14% below where it traded on June 23, the day of the referendum.

In the U.S., the possibility of an interest rate hike before year's end will be on investors' minds again as two Fed presidents are speaking today. Richmond Fed President Jeffrey Lacker is set to discuss the economic outlook for October at the West Virginia Economic Outlook Conference in Charleston, W.V. Later on, Chicago Fed President Charles Evans will be speaking to the CFA Society in New Zealand.

Just when you thought Mylan's (MYL) EpiPen controversy had subsided, it resurfaces. The company's half-price version of its live-saving allergy treatment will be available by the end of this year, potentially months later than a timeline Mylan gave in August, Bloomberg has reported. The cheaper version of the EpiPen shot will cost $300. Mylan spokeswoman Nina Devlin told Bloomberg that Mylan expected the so-called authorized generic EpiPen this year, "once we have assured that sufficient inventory will be available to meet anticipated orders."

In earnings new, Darden Restaurants (DRI) posted better-than-expected earnings and raised its guidance for the full year. The company reported earnings of $0.88 per share, surpassing analysts' estimates of $0.82 per share. Revenue of $1.71 billion was just below Wall Street's forecast of $1.72 billion. The owner of Olive Garden and LongHorn Steakhouse updated its fiscal 2017 outlook. Darden now expects EPS between $3.87 and $3.97, compared with its previous outlook range of $3.80 to $3.90. Shares jumped 4% in premarket trading on the report.

Finally, Alphabet's (GOOGL) Google is set to unveil a number of new tech devices at an event in San Francisco at 12 P.M. ET. Two new smartphones are expected to be introduced as well as Google Assistant, an internet-connected personal-assistant similar to Amazon's (AMZN) Echo. (Alphabet is a holding in Jim Cramer's Action Alerts PLUS portfolio; Amazon is a holding in TheStreet's Growth Seeker portfolio).

TheStreet will be live-blogging the event so check our home page to follow it and submit questions.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long GOOGL stock.

Growth Seeker is long AMZN stock. 

TAGS: Investing | U.S. Equity | Financial Services | Consumer Staples | Technology | Healthcare | Consumer Discretionary | Futures | Earnings

More from Healthcare

Moderna Now Looks Like an Effective Long Trade With Few Side Effects

Bruce Kamich
Jan 14, 2021 12:06 PM EST

MRNA has corrected its big November rally and now looks ready to start a fresh advance, according to the charts.

Pacific Biosciences Reaches Our Price Target: Now What?

Bruce Kamich
Jan 13, 2021 12:19 PM EST

Let's check out the charts and technical indicators.

Emergent BioSolutions Is Looking Stronger

Bruce Kamich
Jan 12, 2021 10:37 AM EST

Here's an update on EBS shares.

Danaher Could Trade Higher

Bruce Kamich
Jan 11, 2021 2:50 PM EST

I do not find enough technical reasons to recommend new long positions at this point in time.

Here's Why Eli Lilly Broke to the Upside

Bruce Kamich
Jan 11, 2021 1:00 PM EST

Let's review the charts and indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • 08:35 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/13/2021

    Lower highs... SPX (Long-Term View) The 1/8/2...
  • 08:07 AM EST GARY BERMAN

    Tuesday Morning Fibocall for 1/12/2021

    Watch if the recent trend of lower highs continues...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login